유럽의 기능유전체학 시장 : 분석 및 예측(2023-2033년)

The Europe Functional Genomics Market Expected to Reach $10.69 Billion by 2033

Introduction to Europe Functional Genomics Market

In 2023, the Europe functional genomics market was valued at $3.01 billion, and it is expected to reach $10.69 billion by 2033, growing at a CAGR of 13.52% during the forecast period 2023-2033. The functional genomics market is poised for growth, primarily propelled by its expanding applications, particularly in the realms of targeted therapy and precision medicine.

Market Introduction

The functional genomics market in Europe is experiencing notable growth driven by advancements in genomic research and rising demand for personalized medicine. Functional genomics involves studying how genes interact with each other and the environment to understand biological functions. With Europe's strong presence in biotechnology and life sciences, coupled with significant investments in research and development, the region is witnessing a surge in genomic studies aimed at unraveling disease mechanisms and developing targeted therapies. Moreover, collaborations between academic institutions, biotech companies, and government agencies are fostering innovation and driving market expansion. Additionally, increasing adoption of high-throughput sequencing and gene editing technologies further propels the functional genomics market. As Europe continues to lead in genomic research, the functional genomics market is poised for continued growth, offering promising opportunities for advancements in healthcare and biotechnology.

Market Segmentation:

Segmentation 1: by Country

• Germany
• France
• U.K.
• Italy
• Spain
• Rest-of-Europe

How can this report add value to an organization?

Product/Innovation Strategy: The report considers functional genomics kits and assays-based companies. The industry is seeing constant development and product launches with new and innovative upgrades. Additionally, new discoveries of more efficient instruments and tools of functional genomics are increasing researchers' trust in functional genomics.

Growth/Marketing Strategy: The key components in Europe functional genomics are the kits and assays along with the instruments for sample analysis. The advancements in the overall functional genomics ecosystem are influencing the growth of this market.

Competitive Strategy: The key players in the Europe functional genomics market have been analyzed and profiled in the study, consisting of most product-based companies. Moreover, a detailed competitive benchmarking of the players operating in the Europe functional genomics market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on thorough secondary research, which includes analyzing company coverage, product portfolio, market penetration, and insights gathered from primary experts.

Some prominent names established in this market are:

• F. Hoffmann-La Roche Ltd
• Merck KGaA
• QIAGEN

Table of Contents

Executive Summary

1 Markets

• 1.1 Product Definition
• 1.2 Inclusion and Exclusion Criteria
• 1.3 Market Scope
  • 1.3.1 Scope of the Study
  • 1.3.2 Key Questions Answered in the Report
• 1.4 Research Methodology
  • 1.4.1 Functional Genomics Market: Research Methodology
  • 1.4.2 Data Sources
  • 1.4.3 Market Estimation Model
  • 1.4.4 Criteria for Company Profiling

2 Market Overview

• 2.1 Functional Genomics Workflow Analysis
• 2.2 Future Potential
• 2.3 Impact of Functional Genomics
  • 2.3.1 Gene Therapy
  • 2.3.2 Drug Discovery and Development
  • 2.3.3 Gene Expression
  • 2.3.4 Single-Cell Analysis

3 Region

• 3.1 Overview
• 3.2 Europe
  • 3.2.1 Germany
  • 3.2.2 France
  • 3.2.3 U.K.
  • 3.2.4 Italy
  • 3.2.5 Spain
  • 3.2.6 Rest-of-Europe

4 Company Profiles

• 4.1 Overview
• 4.2 F. Hoffmann-La Roche Ltd
  • 4.2.1 Company Overview
  • 4.2.2 Role of F. Hoffmann-La Roche Ltd in the Functional Genomics Market
  • 4.2.3 Financials
  • 4.2.4 Key Insights about the Financial Health of the Company
  • 4.2.5 Recent Developments
  • 4.2.6 Analyst Perspective
• 4.3 Merck KGaA
  • 4.3.1 Company Overview
  • 4.3.2 Role of Merck KGaA in the Functional Genomics Market
  • 4.3.3 Financials
  • 4.3.4 Key Insights about the Financial Health of the Company
  • 4.3.5 Analyst Perspective
• 4.4 QIAGEN
  • 4.4.1 Company Overview
  • 4.4.2 Role of QIAGEN in the Functional Genomics Market
  • 4.4.3 Financials
  • 4.4.4 Key Insights about the Financial Health of the Company
  • 4.4.5 Recent Developments
  • 4.4.6 Analyst Perspective